Semaglutide 0.5 mg
Sponsors
Novo Nordisk A/S, Wei Hu, RenJi Hospital, Taipei Veterans General Hospital, Taiwan, Chinese University of Hong Kong
Conditions
Acute Ischemic StrokeCoronary Arterial Disease (CAD)DiabetesDiabetes Mellitus, Type 2Endovascular TreatmentGlucagon-Like Peptide-1 Receptor AgonistsLarge Vessel OcclusionNeuroprotective Drugs
Phase 1
Phase 3
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)
CompletedNCT03061214
Start: 2017-08-28End: 2019-04-15Updated: 2021-03-02
Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment
Not yet recruitingNCT06788626
Start: 2025-02-28End: 2028-02-29Target: 390Updated: 2025-01-23
Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial
Not yet recruitingNCT07030621
Start: 2025-07-01End: 2028-01-31Target: 436Updated: 2025-06-22
Phase 4
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms
Not yet recruitingNCT07073053
Start: 2025-10-01End: 2028-07-31Target: 60Updated: 2025-07-18
GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis
Not yet recruitingNCT07251556
Start: 2025-12-01End: 2027-01-01Target: 40Updated: 2025-12-02